Stock GILD34 GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Gilead Sciences, Inc. Sao Paulo

Equities

GILD34

BRGILDBDR000

Market Closed - Sao Paulo
Other stock markets
 11:01:53 2024-05-31 EDT 		5-day change 1st Jan Change
166.5 BRL -3.89% Intraday chart for Gilead Sciences, Inc. -2.01% -13.51%
05-31 Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival RE
05-31 Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival
RE
Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients
MT
Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study
CI
Gilead Sciences Says Phase 3 Trial in Urothelial Cancer Misses Primary Target
MT
Gilead's Trodelvy fails to meet main goal in late-stage study
RE
Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study
CI
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
CI
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
MT
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV
CI
News Highlights : Top Company News of the Day - Friday at 1 AM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 11 PM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 9 PM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 5 PM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 7 PM ET
DJ
Gilead Sciences Q1 Tops Estimates, Updates Outlook
MT
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
DJ
(GILD) GILEAD SCIENCES Forecasts Fiscal Year 2024 EPS Range $3.45 - $3.85
MT
Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 Revenue $6.69B, vs. Street Est of $6.348B
MT
Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.
CI
Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD34 Stock
  5. News Gilead Sciences, Inc.
  6. Highlights